TurnerTrends Stock Rating Report for BCRX
Data valid for week beginning May 05, 2008
|
BCRX [News]
|
BioCryst Pharmaceuticals Inc
|
Company Profile
"BioCryst Pharmaceuticals, Inc. engages in the design, optimization, and development of novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). This product is in Phase IIa trial for patients with T-cell leukemia and a combination IV, and a Phase I pharmacokinetic trial in healthy volunteers. Additionally, Fodosine is in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma, a Phase II trial in chronic lymphocytic leukemia, and a Phase I-II trial in B-cell acute lymphoblastic leukemia. The company's pipeline products include PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, Neuraminidase Inhibitor (peramivir), and Tissue Factor-Factor VIIa Inhibitors. PNP Inhibitor (BCX-4208), completed a Phase I single dose pharmacokinetic trial, and is intended for the treatment of T-cell mediated autoimmune diseases, including psoriasis. Hepatitis C Polymerase Inhibitor, a product under preclinical stage, is intended for the treatment of viral infections. Peramivir, a product under preclinical stage, is intended for the treatment of strains of influenza, including the avian strain H5N1. Tissue Factor-Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated with cardiovascular procedures. The company has an agreement with Green Cross Corp. for the development and commercialization of potent influenza neuraminidase inhibitor. BioCryst Pharmaceuticals was co-founded by Charles E. Bugg and William M. Spencer, III in 1986. The company is based in Birmingham, Alabama."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Latest News
| Thu, 8 May 2008 20:42:27 Etc/GMT | Thursday's Winners & Losers: Durect (at TheStreet.com) | | Thu, 8 May 2008 20:39:00 Etc/GMT | Health Winners & Losers: Barr (at TheStreet.com) | | Thu, 8 May 2008 16:49:09 Etc/GMT | BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement (EDGAR Online) | | Thu, 8 May 2008 15:45:13 Etc/GMT | BioCryst reports $13.1M net loss (at bizjournals.com) | | Thu, 8 May 2008 11:30:00 Etc/GMT | BioCryst Reports First Quarter 2008 Financial Results and Clinical Update (PR Newswire) | | Thu, 8 May 2008 11:08:11 Etc/GMT | Q1 2008 BioCryst Pharmaceuticals Earnings Release - Before Market Open (CCBN) | | Thu, 1 May 2008 18:18:00 Etc/GMT | BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008 (PR Newswire) | | Thu, 17 Apr 2008 17:25:08 Etc/GMT | SEC: BioCryst's CEO Stonehouse made $1.5M in '07 (at bizjournals.com) | | Mon, 24 Mar 2008 23:10:10 Etc/GMT | BioCryst Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript (at Seeking Alpha) | | Sat, 8 Mar 2008 14:04:48 Etc/GMT | BIOCRYST PHARMACEUTICALS INC Financials (EDGAR Online Financials) | | Wed, 5 Mar 2008 15:17:25 Etc/GMT | New Star Analyst Rankings for BIOCRYST PHARM INC (StarMine) | | Tue, 4 Mar 2008 17:14:50 Etc/GMT | BioCryst narrows its net losses in 2007 (at bizjournals.com) | | Tue, 4 Mar 2008 13:07:34 Etc/GMT | BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (EDGAR Online) | | Tue, 4 Mar 2008 13:00:00 Etc/GMT | BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update (PR Newswire) | | Thu, 28 Feb 2008 19:00:00 Etc/GMT | BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008 (PR Newswire) | | Tue, 26 Feb 2008 18:35:57 Etc/GMT | 5 Stocks That Swayed the Skeptics (at Motley Fool) | | Thu, 10 Jan 2008 22:08:20 Etc/GMT | BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (EDGAR Online) | | Thu, 6 Dec 2007 12:28:39 Etc/GMT | BioCryst discontinues intravenous drug trial (at MarketWatch) | | Tue, 13 Nov 2007 19:06:48 Etc/GMT | BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of (EDGAR Online) | | Thu, 8 Nov 2007 21:37:33 Etc/GMT | Thursday's Health Winners & Losers (at TheStreet.com) | News provided by Yahoo! Finance |
|
